Zydus Lifesciences · NSE: ZYDUSLIFE · BSE: 532321

Q4 FY22 results · Jan–Mar 2022

Zydus Lifesciences reported revenue from operations of ₹3,863.80 crore (up 0.4% from Q4 FY21) and net profit of ₹453.30 crore (down 38.4% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY22	Q4 FY21	YoY	Q3 FY22	QoQ
Revenue from operations	3,863.80	3,846.70	+0.4%	3,655.00	+5.7%
Other income	79.10	(40.30)	Turned profit	60.80	+30.1%
Total income	3,942.90	3,806.40	+3.6%	3,715.80	+6.1%
Profit before share of associates & JVs and tax	572.90	530.00	+8.1%	599.00	−4.4%
Share of profit/(loss) of associates & JVs	4.60	3.80		22.30
Net profit for the period	453.30	735.40	−38.4%	510.60	−11.2%
Attributable to shareholders of the company	397.40	679.00	−41.5%	500.40	−20.6%
EPS, basic (₹)	3.88	6.63	−41.5%	4.89	−20.7%
Net margin (%)	11.7	19.1		14.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY22	Q4 FY21	YoY	Q3 FY22	QoQ
Revenue from operations	2,019.30	2,018.80	+0.0%	1,830.30	+10.3%
Other income	53.70	(26.90)	Turned profit	25.90	+107.3%
Total income	2,073.00	1,991.90	+4.1%	1,856.20	+11.7%
Profit before tax	346.50	441.80	−21.6%	239.90	+44.4%
Net profit for the period	246.90	464.70	−46.9%	197.00	+25.3%
EPS, basic (₹)	2.41	4.54	−46.9%	1.92	+25.5%
Net margin (%)	12.2	23.0		10.8

Consolidated

Filed with BSE: 20 May 2022, 18:15 IST
Board meeting: 20 May 2022
Period: 01 Jan 2022 to 31 Mar 2022
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 20 May 2022, 18:15 IST
Board meeting: 20 May 2022
Period: 01 Jan 2022 to 31 Mar 2022
Review status: Unaudited
Source: XBRL filing on BSE